Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

Phase 3

EMBER-3; NCT04975308

Breast Cancer

Selective ER Degrader


A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator’s Choice of Endocrine Therapy in Patients With Estrogen-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy*

NCT04975308
Key Inclusion Criteria
  • Diagnosis of estrogen-receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer
  • Disease that has demonstrated progression on or after an aromatase inhibitor alone or in combination with a CDK4 & 6 inhibitor
  • Deemed appropriate for treatment with endocrine therapy
  • Response Evaluation Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable bone-only disease)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • ≥18 years of age
  • Adequate renal, hematologic, and hepatic organ function
  • If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
  • Able to swallow capsules/tablets
Key Exclusion Criteria
  • Prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy), fulvestrant, or any investigational ER-directed therapy (including SERDs and non-SERDs), any PI3K, mTOR, or AKT inhibitor
  • Visceral crisis, lymphangitic spread within the lung, or any evidence of leptomeningeal disease
  • Symptomatic or untreated brain metastasis
  • Serious preexisting medical conditions
  • Known allergic reaction against any of the components of the study treatment
*
This clinical trial is being conducted globally.
LY3484356 is administered PO.
Exemestane is administered PO.
§
Fulvestrant is administered intramuscularly.
Contact the Lilly Oncology Clinical Trial Navigation Service

Visit www.clinicaltrials.gov for more information on this trial.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.